Ovid Therapeutics Inc. is a New York-based biotech company using its BoldMedicine® approach to develop medicines that transform the lives of people affected by rare neurological disorders. Ovid seeks to couple deep CNS experience with emerging advances in genetics and the pathways of the brain to build a leading neuroscience pipeline. For more information, please visit www.ovidrx.com. Review our community guidelines: http://www.ovidrx.com/community-guidelines/
Location: United States, New York
Employees: 11-50
Total raised: $103.2M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.02.2019 | - | $28.2M | - |
| 11.08.2015 | Series B | $75M | - |
Mentions in press and media 15
| Date | Title | Description |
| 25.06.2025 | Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties | Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties Wed, Jun 25, 2025 14:02 CET Report this content Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Roya... |
| 15.11.2024 | RFK Jr vow to purge FDA sets up collision with Big Pharma | RFK Jr vow to purge FDA sets up collision with Big Pharma By Ahmed Aboulenein and Michael ErmanNovember 15, 202411:08 AM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link Item 1 of 2 Robert F. Kenned... |
| 02.10.2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| 14.03.2024 | Rare Disease Advocates Learn to Accelerate Therapeutic Development at 9th RARE Drug Development Symposium | RARE Drug Development Symposium The RARE Drug Development Symposium, hosted by Global Genes and the Orphan Disease Center of the University of Pennsylvania, equips advocates with the knowledge, skills and connections they need to advance th... |
| 08.03.2024 | Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results | - |
| 09.02.2022 | Healx and Ovid Therapeutics enter strategic partnership | Healx and Ovid Therapeutics enter strategic partnership 09-02-2022 New York, NY and Cambridge, UK Ovid Therapeutics, a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological diseases... |
| 05.06.2019 | New BIO chair hopes for greater policy focus on rare diseases | In an interview at the BIO conference in Philadelphia Wednesday, Levin said rare diseases will be a particular area of interest for him at the organization. Ovid is also focused on development of rare neurological diseases, and its most adv... |
| 05.05.2017 | Term Sheet — Friday, May 5 | CRYPTO-SPLAINING Last week a very confusing press release crossed my radar. It read: “The Argon Group is working on the first secondary market raise by ICO. The company, Storj had one of the most successful ICOs several years ago, returning... |
| 26.04.2017 | Term Sheet — Wednesday, April 26 | ET CETERA Good morning! This the third-largest ever “ed tech” deal, aside from German publishing giant Bertelsmann’s $230 million stake in HotChalk and a $200 million fundraising by TutorGroup, an Alibaba-backed English tutoring startup. Th... |
| 13.05.2016 | Big Pharma Innovation in Small Places | As a vice president of the $38 billion (sales) French drug company Sanofi, Victoria Richon witnessed constant reorganizations that affected her oncology drug development program. Teams shuffled, priorities shifted, and processes changed. S... |
Show more